English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03215030 /

TAK-573-1501

A Phase 1/2 Open-Label Study To Investigate The Safety And Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of TAK-573 As A Single Agent In Patients With Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: